Atlas Trials

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

Clinical trial NCT04047472 · COMPLETED

Trial details

NCT number
NCT04047472
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Neovascular Age-Related Macular Degeneration
Start date
2019-11-29
Primary completion
2024-02-28
Enrollment
397

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.